| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8446826 | European Journal of Cancer | 2012 | 9 Pages |
Abstract
Docetaxel-estramustine can be combined safely with standard therapy in high-risk prostate cancer, with a promising PSA response rate and no negative impact on quality of life after 1Â year. Long-term follow-up is required to assess the impact on relapse and survival.
Keywords
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Karim Fizazi, Francois Lesaunier, Remy Delva, Gwenaëlle Gravis, Frederic Rolland, Frank Priou, Jean-Marc Ferrero, Nadine Houedé, Loïc Mourey, Christine Theodore, Ivan Krakowski, Jean-François Berdah, Marjorie Baciuchka, Brigitte Laguerre,